ALB and neoplasm: To address this challenging issue, pharmaceutical scientists are now focusing on dimerization or trimerization of nanobodies (e.g., in the case of caplacizumab), fusing them in their monomeric form with an albumin‐targeting nanobody moiety [48, 49, 50], or administering then with tumor penetrating peptides, which can enhance vascular and tissue permeability through augmentation of endocytosis pathways [51].